|
|
|
Issue Open Date
|
22-Feb-24
|
|
|
|
Issue Closing Date
|
26-Feb-24
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
177
-
186
|
|
|
|
Minimium Application No.
|
80
|
|
|
|
Issue Size (Shares)
|
28233323
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
Objective
|
|
1. Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company from banks and financial institutions; and2. General corporate purposes;
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
4234999
|
46658640
|
11.0173910312612
|
|
Qualified Institutional Buyers
|
5646664
|
97684000
|
17.2994178509647
|
|
Retail Individual Investors
|
9881664
|
24129600
|
2.44185594652884
|
|
|
|
|
Business Description
We are one of the key regional corporate healthcare companies in Eastern India in terms of number of beds and hospitals as of Fiscal Year 2023. (Source: CRISIL Report) We operate a chain of mid-sized full service multispecialty hospitals in Eastern India under the brand and provide integrated healthcare services, with a focus on secondary and tertiary care. As of June 30, 2023, we operate four full service multispecialty hospitals, with a total capacity of 561 beds. We offer a comprehensive range of healthcare services across over 35 specialties and super specialties, including internal medicine and diabetology, nephrology (including renal transplants), laparoscopic and general surgery, gynaecology and obstetrics, critical care, gastroenterology, orthopaedics and joint replacements, interventional cardiology, neurology, neurosurgery, paediatrics, and neonatology. Each of our hospitals also provides integrated diagnostic services and pharmacies that cater to our patients. We strategically focus on the relatively under-penetrated healthcare market in Eastern India where we have presence in three cities which we believe has provided us an understanding of regional nuances, patient culture and the mindset of medical professionals and where there is under-penetration of quality and affordable healthcare services. This has enabled our Company to deliver robust financial performance, with our revenue from operations (ex-COVID) growing at a CAGR of 53.87% over Fiscal Year 2021 to Fiscal Year 2023 and ROCE being 26.09% for Fiscal Year 2023.
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
53806500
|
|
|
|
Offered to Public
|
28233323
|
|
|
|
Promoter's Holding (Pre-Issue)
|
67.34
|
|
|
|
Promoter's Holding (Post-Issue)
|
65.57
|
|
|
|
|
|
|
|
|
|
|
Address |
J C-25
Sector I I I
Salt Lake
Kolkata,
West Bengal,
700098
Phone : 033 40507000
Email : ghl.cosec@gptgroup.co.in
Website : www.ilshospitals.com
|
|
|
Registrar |
Link Intime India Pvt Ltd.
C 101
247 Park
L B S Marg
Vikhroli (West)
Mumbai
|
|
|
Listed at |
|
BSE, NSE
|
|
|
Lead Manager |
|
JM Financial Ltd.
|
|
|
Promoters |
Dwarika Prasad Tantia
GPT Sons Pvt Ltd.
Om Tantia
Shree Gopal Tantia
|
|
